Investor Presentaiton
Novo NordiskⓇ
103
Investor presentation Full year 2022
AD patient journey is complex and underscores key barriers to
overcome for Novo Nordisk to be successful
Million
Significant and growing
unmet need
Hurdles
80
60
40
40
20
20
0
Y
Y
Early symptoms
dismissed as normal
ageing
Complex tests and
limited screening/
diagnosing skills
Lack of prognostic
markers and simple
tests
Limited DMT
options
Few patients
AD
receiving
diagnosis
prevalence
•
•
Support healthcare
system preparedness
Larger number of AD patients
expected to enter the system
May lead to significant bottle-
necks and delay to patient care
Market preparation priorities
Increase diagnosis rate
Indicates expected invesment level
Support NITs development, e.g.
blood-based/digital biomarkers
Increase AD education and
access to screening tools for
PCPs and HCP insight
Evidence generation
Evidence to better understand the
•
impact of delaying disease
progression
role of neuroinflammation
in disease progression
Prevalence Diagnosed Eligible
patients
patients
MCI
Mild dementia
Note: MCI and Mild dementia in the graph are both due to AD.
AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; DMT: Disease-modifying treatment; PCP: primary care physicians; NITs: Non-invasive diagnostics; HCP: Healthcare professional
Source: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460)View entire presentation